Molecular imaging, pharmacokinetics, and dosimetry of 111In-AMBA in human prostate tumor-bearing mice

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Chang, Chih Hsien ^a,b   Ho, Chung Li ^a   Liu, I Hsiang ^a   Wu, Yu Hsien ^a   Chen, Liang Cheng ^a   Chen, Chun Lin ^a   Lee, Wan Chi ^a   Chuang, Cheng Hui ^a   Lee, Te Wei ^a   Lin, Wuu Jyh ^a,b   Shen, Lie Hang ^a  

^a INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMBA IN 111; GASTRIN RELEASING PEPTIDE RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BOMBESIN; BOMBESIN RECEPTOR; DIAGNOSTIC AGENT; DO3A CH2CO G 4 AMINOBENZOYL Q W A V G H L M NH2; DO3A-CH2CO-G-4-AMINOBENZOYL-Q-W-A-V-G-H-L-M-NH2; INDIUM; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG UPTAKE; EXPERIMENTAL NEOPLASM; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MICROSPECTROPHOTOMETRY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; CELL STRAIN HEK293; HALF LIFE TIME; ISOTOPE LABELING; METABOLISM; METHODOLOGY; MOUSE MUTANT; PROSTATE TUMOR; RADIOMETRY; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE; XENOGRAFT;

MUS;

ANIMALS; BOMBESIN; CELL LINE, TUMOR; HALF-LIFE; HEK293 CELLS; HUMANS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; MALE; MICE; MICE, SCID; MOLECULAR IMAGING; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; RADIOMETRY; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRANSPLANTATION, HETEROLOGOUS;

EID: 80052671789     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/101497     Document Type: Article

References (37)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M. J., Cancer statistics, 2009 CA Cancer Journal for Clinicians 2009 59 4 225 249
2. Erspamer V., Erpamer G. F., Inselvini M., Some pharmacological actions of alytesin and bombesin Journal of Pharmacy and Pharmacology 1970 22 11 875 876
3. Kroog G. S., Jensen R. T., Battey J. F., Mammalian bombesin receptors Medicinal Research Reviews 1995 15 5 389 417
4. Ohki-Hamazaki H., Iwabuchi M., Maekawa F., Development and function of bombesin-like peptides and their receptors International Journal of Developmental Biology 2005 49 2-3 293 300 (Pubitemid 40917351)
5. Jensen R. T., Battey J. F., Spindel E. R., Benya R. V., International union of pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states Pharmacological Reviews 2008 60 1 1 42 (Pubitemid 351439216)
6. Maddalena M. E., Fox J., Chen J., Feng W., Cagnolini A., Linder K. E., Tweedle M. F., Nunn A. D., Lantry L. E., Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression Journal of Nuclear Medicine 2009 50 12 2017 2024
7. Nagy A., Schally A. V., Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a smarter chemotherapy Current Pharmaceutical Design 2005 11 9 1167 1180 (Pubitemid 40403375)
8. Willmann J. K., van Bruggen N., Dinkelborg L. M., Gambhir S. S., Molecular imaging in drug development Nature Reviews Drug Discovery 2008 7 7 591 607 (Pubitemid 351927724)
9. Lammers T., Kiessling F., Hennink W. E., Storm G., Nanotheranostics and image-guided drug delivery: current concepts and future directions Molecular Pharmaceutics 2010 7 6 1899 1912
10. Markwalder R., Reubi J. C., Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation Cancer Research 1999 59 5 1152 1159 (Pubitemid 29135980)
11. Ho C.-L., Chen L.-C., Lee W.-C., Chiu S. -P., Hsu W. -C., Wu Y. -H., Yeh C. -H., Stabin M. G., Jan M. -L., Lin W. -J., Lee T. -W., Chang C. -H., Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111 In-[DTPA 1, Lys 3, Tyr 4 ]-bombesin analog in human prostate tumor-bearing mice Cancer Biotherapy and Radiopharmaceuticals 2009 24 4 435 443
12. Breeman W. A. P., De Jong M., Bernard B. F., Kwekkeboom D. J., Srinivasan A., Van Der Pluijm M. E., Hofland L. J., Visser T. J., Krenning E. P., Pre-clinical evaluation of [ 111 In-DTPA-Pro 1, Tyr 4 ]bombesin, a new radioligand for bombesin-receptor scintigraphy International Journal of Cancer 1999 83 5 657 663 (Pubitemid 29508046)
13. Breeman W. A. P., De Jong M., Erion J. L., Bugaj J. E., Srinivasan A., Bernard B. F., Kwekkeboom D. J., Visser T. J., Krenning E. P., Preclinical comparison of In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy Journal of Nuclear Medicine 2002 43 12 1650 1656 (Pubitemid 35424990)
14. De Visser M., Bernard H. F., Erion J. L., Schmidt M. A., Srinivasan A., Waser B., Reubi J. C., Krenning E. P., De Jong M., Novel 111 In-labelled bombesin analogues for molecular imaging of prostate tumours European Journal of Nuclear Medicine and Molecular Imaging 2007 34 8 1228 1238 (Pubitemid 47296771)
15. Tweedle M. F., Peptide-targeted diagnostics and radiotherapeutics Accounts of Chemical Research 2009 42 7 958 968
16. Kereiakes J. G., Rao D. V., Auger electron dosimetry: report of AAPM Nuclear Medicine Committee Task Group No. 6 Medical Physics 1992 19 6 1359 1360
17. Liu I.-H., Chang C.-H., Ho C.-L., Chiu S. -P., Lee W. -C., Chang T. -J., Chen L. -C., Wu Y. -H., Chuang C. -H., Fu Y. -K., Lee T. -W., Multimodality imaging and preclinical evaluation of 177 Lu-AMBA for human prostate tumours in a murine model Anticancer Research 2010 30 10 4039 4048
18. Garrison J. C., Rold T. L., Sieckman G. L., Naz F., Sublett S. V., Figueroa S. D., Volkert W. A., Hoffman T. J., Evaluation of the pharmacokinetic effects of various linking group using the 111 In-DOTA-X-BBN(7-14)NH structural paradigm in a prostate cancer model Bioconjugate Chemistry 2008 19 9 1803 1812
19. Schroeder R. P. J., Mller C., Reneman S., Melis M. L., Breeman W. A. P., de Blois E., Bangma C. H., Krenning E. P., van Weerden W. M., de Jong M., A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues European Journal of Nuclear Medicine and Molecular Imaging 2010 37 7 1386 1396
20. Mansi R., Wang X., Forrer F., Kneifel S., Tamma M. L., Waser B., Cescato R., Reubi J. C., Maecke H. R., Evaluation of a 1,4,7,10-tetraazacyclododecane-1, 4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides Clinical Cancer Research 2009 15 16 5240 5249
21. Zhang H., Chen J., Waldherr C., Hinni K., Waser B., Reubi J. C., Maecke H. R., Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with Indium-111, Lutetium-177, and Yttrium-90 for targeting bombesin receptor-expressing tumors Cancer Research 2004 64 18 6707 6715 (Pubitemid 39302601)
22. Bakker W. H., Albert R., Bruns C., Breeman W. A. P., Hofland L. J., Marbach P., Pless J., Pralet D., Stolz B., Koper J. W., Lamberts S. W. J., Visser T. J., Krenning E. P., [ 111 In-DTPA-D-Phe 1 ]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation Life Sciences 1991 49 22 1583 1591
23. Smith C. J., Gali H., Sieckman G. L., Hayes D. L., Owen N. K., Mazuru D. G., Volkert W. A., Hoffman T. J., Radiochemical investigations of 177 Lu-DOTA-8-Aoc-BBN[7-14]NH: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells Nuclear Medicine and Biology 2003 30 2 101 109 (Pubitemid 36293710)
24. Stabin M. G., Siegel J. A., Physical models and dose factors for use in internal dose assessment Health Physics 2003 85 3 294 310 (Pubitemid 36999340)
25. Molina-Trinidad E. M., Murphy C. A. D., Ferro-Flores G., Murphy-Stack E., Jung-Cook H., Radiopharmacokinetic and dosimetric parameters of 188 Re-lanreotide in athymic mice with induced human cancer tumors International Journal of Pharmaceutics 2006 310 1-2 125 130 (Pubitemid 43287975)
26. International Commission on Radiological Units and Measurements, Absorbed-Dose Specification in Nuclear Medicine, ICRU Report 67 Journal of the ICRU 2002 2 1
27. Chang C. H., Chou TA. K., Yang C. Y., Chang T. J., Wu YU. H., Lee TE. W., Biodistribution and pharmacokinetics of transgenic pig-produced recombinant human factor IX (rhFIX) in rats In Vivo 2008 22 6 693 698
28. Sotomayor S., Muoz-Moreno L., Carmena M. J., Schally A. V., Snchez-Chapado M., Prieto J. C., Bajo A. M., Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095) International Journal of Cancer 2010 127 8 1813 1822
29. Cornelio D. B., Roesler R., Schwartsmann G., Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy Annals of Oncology 2007 18 9 1457 1466 (Pubitemid 47365477)
30. Maina T., Nock B. A., Zhang H., Nikolopoulou A., Waser B., Reubi J. C., Maecke H. R., Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs Journal of Nuclear Medicine 2005 46 5 823 830
31. Scemama J. L., Zahidi A., Fourmy D., Interaction of [ 125 I]-Tyr-bombesin with specific receptors on normal human pancreatic membranes Regulatory Peptides 1986 13 2 125 132 (Pubitemid 16179139)
32. Waser B., Eltschinger V., Linder K., Nunn A., Reubi J. C., Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer Lu-AMBA European Journal of Nuclear Medicine and Molecular Imaging 2007 34 1 95 100 (Pubitemid 44885559)
33. Smith C. J., Volkert W. A., Hoffman T. J., Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes Nuclear Medicine and Biology 2005 32 7 733 740 (Pubitemid 41502979)
34. Louis S., Octreoscan kit for the preparation of indium-111 pentetreotide [product monograph]. 1995
35. Ferrari M., Cremonesi M., Bartolomei M., Bodei L., Chinol M., Fiorenza M., Tosi G., Paganelli G., Dosimetric model for locoregional treatments of brain tumors with Y-conjugates: clinical application with Y-DOTATOC Journal of Nuclear Medicine 2006 47 1 105 112 (Pubitemid 46768519)
36. Krenning E. P., Koolj P. P. M., Bakker W. H., Breeman W. A. P., Postema P. T. E., Kwekkeboom D. J., Oei H. Y., De Jong M., Visser T. J., Reijs A. E. M., Lamberts S. W. J., Radiotherapy with a radiolabeled somatostatin analogue, [ 111 In-DTPA-D-Phe 1 ]-Octreotide. A case history Annals of the New York Academy of Sciences 1994 733 496 506
37. Lantry L. E., Cappelletti E., Maddalena M. E., Fox J. S., Feng W., Chen J., Thomas R., Eaton S. M., Bogdan N. J., Arunachalam T., Reubi J. C., Raju N., Metcalfe E. C., Lattuada L., Linder K. E., Swenson R. E., Tweedle M. F., Nunn A. D., 177 Lu-AMBA: synthesis and characterization of a selective 177 Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer Journal of Nuclear Medicine 2006 47 7 1144 1152 (Pubitemid 47558898)